Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

BOSTON, May 14, 2024 (GLOBE NEWSWIRE) --  Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 2^nd Annual BioConnect Investor Conference taking place in New York City, NY on May 20, 2024.

Fireside Chat details
Date: Monday, May 20
Time: 11:30 AM ET
Webcast Link: https://journey.ct.events/view/

Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’ Events page.

About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Investor Contact
ir@compasstherapeutics.com

Media Contact
Anna Gifford, Senior Communications Manager
media@compasstherapeutics.com
617-500-8099